Nervous Disorder TRIZ Cases

Disrupting peroxisome biogenesis factor proteins redirects metabolic flux to boost polyunsaturated fatty acid yield despite genetic complexity.

Palmitoylethanolamide and beta-caryophyllene activate CB2 receptors to boost anti-inflammatory action in a unified pharmaceutical composition.

Antibody-coated particles deliver therapeutic agents to affected neurons, resolving delivery complexity while reducing mutant Huntingtin levels.

Recombinant neurotropic viral vectors deliver transgenes via brain injection sites.

PDE1 inhibitors increase cAMP and cGMP levels to treat psychiatric disorders where current therapies lack efficacy.

A specific neural regeneration peptide sequence reduces seizure duration and frequency while enhancing normal neuron volume.

A synthetic peptide sequence blocks toxic protein interactions to protect cellular mitochondria.

Administering signaling modulators to fetal glial progenitor cells resolves migration bottlenecks in adult brain tissue, enabling effective remyelination.

Circulating miRNA biomarkers enable non-invasive detection of Alzheimer's Disease by replacing complex clinical criteria with accessible molecular assays.

An irradiation therapy apparatus combines ionization and ultraviolet modules for simultaneous or alternate emission.

Uses natural plant extracts to improve sleep latency and duration while avoiding narcolepsy and drug resistance from benzodiazepines.

Modular dimeric polymeric compounds reduce conjugate complexity while enhancing therapeutic efficacy through standardized linker systems.

Expanded cord blood stem cells induce immune tolerance through selective regulatory T cell expansion.

Incorporating an electrophilic leaving group enables reversible thioether bonding, resolving irreversibility issues in maleimide cross-linkers.

Small molecule soluble epoxide hydrolase inhibitors cross the blood-brain barrier to deliver neuroprotective and anti-inflammatory effects.

Cinnamyl alcohol derivatives increase serotonin release to reduce appetite while avoiding the pungent aftertaste of nonivamide.

Thermosoftening carriers dissolve sticky oxidized phospholipids into homogeneous matrices, preventing leakage and cracking in soft capsules.

Repeated oral administration of high-dose ubiquinol alleviates multiple system atrophy symptoms.

Combines Lactobacillus plantarum probiotics with intranasal oxytocin to modulate gut microbiome composition and central nervous system signaling pathways.

Humanized monoclonal antibodies bind CD100 to block receptor interaction, treating inflammatory diseases.

Exosomal biomarker detection resolves the trade-off between diagnostic accuracy and patient invasiveness by analyzing protein complexes in blood samples.

High affinity antibodies targeting tau phosphorylated at serine 413 utilize optimized variable regions to bind pathological protein species.

Targeting serotonin-related genes with miR-135 addresses limited effectiveness of conventional antidepressants by improving diagnostic precision.

Using copper-64 chloride eliminates complex molecule synthesis while maintaining diagnostic precision and therapeutic effectiveness.

C1-substituted isopropylamine fused heterocyclic mescaline derivatives reduce adverse side effects like panic attacks while maintaining therapeutic benefits.

A nasal formula containing antioxidants and essential oils increases brain serotonin levels in non-human mammals.

A recombinant truncated GLB1 enzyme maintains catalytic activity while eliminating heterogeneous protein truncation issues.

A pharmaceutical composition combines edaravone with specific lipids to deliver neuroprotection.

Hydroxylated psilocybin derivatives reduce adverse side effects like panic attacks while maintaining therapeutic benefits.

Antibodies 10F4 and 3C5 target Aβ globulomers to reduce plaque burden while minimizing cerebral hemorrhages.

A fusion protein combining CRIg extracellular domain with a complement inhibiting domain targets C3b/iC3b to block early cascade activation.

Multispecific antibodies bind transferrin receptors to transport therapeutic agents across the blood-brain barrier.

Segmented oral preparation separates drug layer from adhesive portion to eliminate diffusion barrier and resolve slow absorption lag-time.

Aptamers neutralize pathogenic autoantibodies targeting myelin proteins.

Plasminogen pathway activators catalyze Pro-NGF cleavage into mature nerve growth factor.

Targeting Magi-1 with peptides resolves the need for direct Nav1.8 blockers by controlling channel membrane localization.

Topical pharmaceutical compositions comprising C4-C8 aliphatic diols and triols deliver localized antispasmodic effects directly to muscle tissue.

Roseburia hominis restores immune tolerance and modulates metabolic activity to treat inflammatory disorders.

Placental stem cells suppress T cell proliferation and NK cell activity to prevent immune-mediated rejection in tissue transplants.

Antisense oligonucleotides bind alpha-synuclein mRNA to lower protein levels, addressing off-target safety risks in treatment.

Segmented herbal formulas eliminate drug dependence and painful cliff-like withdrawal while enhancing immune function.

A nutritional agent combining Vitis vinifera and Vaccinium angustifolium extracts to enhance polyphenol bioavailability.

A bifunctional small-molecule degrader recruits autophagy adapter proteins to specific targets.

Biotinylated self-assembling peptides create stable hydrogel scaffolds, resolving biocompatibility and inflammatory response trade-offs in tissue engineering.

Enantiomerically-enriched (-)-nilvadipine reduces amyloid deposition and neurotoxicity.

Neuregulin mediates ErbB receptor signaling to restore peripheral nerve function, resolving therapeutic inefficacy in trauma cases.